Antibiotics in infections of the biliary tract

E. L. Muller, H. A. Pitt, J. E. Thompson, J. E. Doty, L. L. Mann, B. Manchester

Research output: Contribution to journalArticle

Abstract

The combination of a penicillin and an aminoglycoside has been recommended as the initial treatment of choice for patients with infections of the biliary tract. However, elderly, septic, patients with jaundice have a high incidence of renal problems. For this reason, aminoglycoside treatment of these patients must be re-evaluated as newer less nephrotoxic agents become available. We, therefore, performed a prospective, randomized trial of ampicillin plus tobramycin, cefoperazone and piperacillin in patients with biliary tract infections. During a 20 month period, 106 patients with acute cholecystitis (53) or cholangitis (53), or both, received one of these antibiotic regimens for a minimum of five days. In patients with acute cholecystitis, ampicillin plus tobramycin, cefoperazone and piperacillin had clinical cure rates of 85, 95 and 95 percent, respectively. In patients with cholangitis, however, cure rates for the three regimens were 85, 56 (p <0.05 versus ampicillin plus tobramycin) and 60 percent (not significant versus ampicilllin plus tobramycin), respectively. Moreover, 13 percent of the patients receiving cefoperazone had an increased prothrombin time and three of 39 patients receiving this antibiotic had clinical problems with bleeding. Nephrotoxicity was greatest in patients with cholangitis receiving ampicillin plus tobramycin, 10 percent, as compared with 3 percent in those who did not receive an aminoglycoside. This difference, however, was not statistically significant. It was concluded that piperacillin should be considered for antibiotic management of patients with acute cholecystitis and that further studies are necessary in patients with cholangitis to determine whether or not newer agents should replace penicillin and aminoglycoside combinations.

Original languageEnglish (US)
Pages (from-to)285-292
Number of pages8
JournalSurgery Gynecology and Obstetrics
Volume165
Issue number4
StatePublished - 1987
Externally publishedYes

Fingerprint

Biliary Tract
Anti-Bacterial Agents
Infection
Tobramycin
Cholangitis
Aminoglycosides
Ampicillin
Cefoperazone
Piperacillin
Acute Cholecystitis
Penicillins
Prothrombin Time
Jaundice
Hemorrhage
Kidney

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Surgery

Cite this

Muller, E. L., Pitt, H. A., Thompson, J. E., Doty, J. E., Mann, L. L., & Manchester, B. (1987). Antibiotics in infections of the biliary tract. Surgery Gynecology and Obstetrics, 165(4), 285-292.

Antibiotics in infections of the biliary tract. / Muller, E. L.; Pitt, H. A.; Thompson, J. E.; Doty, J. E.; Mann, L. L.; Manchester, B.

In: Surgery Gynecology and Obstetrics, Vol. 165, No. 4, 1987, p. 285-292.

Research output: Contribution to journalArticle

Muller, EL, Pitt, HA, Thompson, JE, Doty, JE, Mann, LL & Manchester, B 1987, 'Antibiotics in infections of the biliary tract', Surgery Gynecology and Obstetrics, vol. 165, no. 4, pp. 285-292.
Muller EL, Pitt HA, Thompson JE, Doty JE, Mann LL, Manchester B. Antibiotics in infections of the biliary tract. Surgery Gynecology and Obstetrics. 1987;165(4):285-292.
Muller, E. L. ; Pitt, H. A. ; Thompson, J. E. ; Doty, J. E. ; Mann, L. L. ; Manchester, B. / Antibiotics in infections of the biliary tract. In: Surgery Gynecology and Obstetrics. 1987 ; Vol. 165, No. 4. pp. 285-292.
@article{b7616684ae7741a48efc4c8747e7a17b,
title = "Antibiotics in infections of the biliary tract",
abstract = "The combination of a penicillin and an aminoglycoside has been recommended as the initial treatment of choice for patients with infections of the biliary tract. However, elderly, septic, patients with jaundice have a high incidence of renal problems. For this reason, aminoglycoside treatment of these patients must be re-evaluated as newer less nephrotoxic agents become available. We, therefore, performed a prospective, randomized trial of ampicillin plus tobramycin, cefoperazone and piperacillin in patients with biliary tract infections. During a 20 month period, 106 patients with acute cholecystitis (53) or cholangitis (53), or both, received one of these antibiotic regimens for a minimum of five days. In patients with acute cholecystitis, ampicillin plus tobramycin, cefoperazone and piperacillin had clinical cure rates of 85, 95 and 95 percent, respectively. In patients with cholangitis, however, cure rates for the three regimens were 85, 56 (p <0.05 versus ampicillin plus tobramycin) and 60 percent (not significant versus ampicilllin plus tobramycin), respectively. Moreover, 13 percent of the patients receiving cefoperazone had an increased prothrombin time and three of 39 patients receiving this antibiotic had clinical problems with bleeding. Nephrotoxicity was greatest in patients with cholangitis receiving ampicillin plus tobramycin, 10 percent, as compared with 3 percent in those who did not receive an aminoglycoside. This difference, however, was not statistically significant. It was concluded that piperacillin should be considered for antibiotic management of patients with acute cholecystitis and that further studies are necessary in patients with cholangitis to determine whether or not newer agents should replace penicillin and aminoglycoside combinations.",
author = "Muller, {E. L.} and Pitt, {H. A.} and Thompson, {J. E.} and Doty, {J. E.} and Mann, {L. L.} and B. Manchester",
year = "1987",
language = "English (US)",
volume = "165",
pages = "285--292",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Antibiotics in infections of the biliary tract

AU - Muller, E. L.

AU - Pitt, H. A.

AU - Thompson, J. E.

AU - Doty, J. E.

AU - Mann, L. L.

AU - Manchester, B.

PY - 1987

Y1 - 1987

N2 - The combination of a penicillin and an aminoglycoside has been recommended as the initial treatment of choice for patients with infections of the biliary tract. However, elderly, septic, patients with jaundice have a high incidence of renal problems. For this reason, aminoglycoside treatment of these patients must be re-evaluated as newer less nephrotoxic agents become available. We, therefore, performed a prospective, randomized trial of ampicillin plus tobramycin, cefoperazone and piperacillin in patients with biliary tract infections. During a 20 month period, 106 patients with acute cholecystitis (53) or cholangitis (53), or both, received one of these antibiotic regimens for a minimum of five days. In patients with acute cholecystitis, ampicillin plus tobramycin, cefoperazone and piperacillin had clinical cure rates of 85, 95 and 95 percent, respectively. In patients with cholangitis, however, cure rates for the three regimens were 85, 56 (p <0.05 versus ampicillin plus tobramycin) and 60 percent (not significant versus ampicilllin plus tobramycin), respectively. Moreover, 13 percent of the patients receiving cefoperazone had an increased prothrombin time and three of 39 patients receiving this antibiotic had clinical problems with bleeding. Nephrotoxicity was greatest in patients with cholangitis receiving ampicillin plus tobramycin, 10 percent, as compared with 3 percent in those who did not receive an aminoglycoside. This difference, however, was not statistically significant. It was concluded that piperacillin should be considered for antibiotic management of patients with acute cholecystitis and that further studies are necessary in patients with cholangitis to determine whether or not newer agents should replace penicillin and aminoglycoside combinations.

AB - The combination of a penicillin and an aminoglycoside has been recommended as the initial treatment of choice for patients with infections of the biliary tract. However, elderly, septic, patients with jaundice have a high incidence of renal problems. For this reason, aminoglycoside treatment of these patients must be re-evaluated as newer less nephrotoxic agents become available. We, therefore, performed a prospective, randomized trial of ampicillin plus tobramycin, cefoperazone and piperacillin in patients with biliary tract infections. During a 20 month period, 106 patients with acute cholecystitis (53) or cholangitis (53), or both, received one of these antibiotic regimens for a minimum of five days. In patients with acute cholecystitis, ampicillin plus tobramycin, cefoperazone and piperacillin had clinical cure rates of 85, 95 and 95 percent, respectively. In patients with cholangitis, however, cure rates for the three regimens were 85, 56 (p <0.05 versus ampicillin plus tobramycin) and 60 percent (not significant versus ampicilllin plus tobramycin), respectively. Moreover, 13 percent of the patients receiving cefoperazone had an increased prothrombin time and three of 39 patients receiving this antibiotic had clinical problems with bleeding. Nephrotoxicity was greatest in patients with cholangitis receiving ampicillin plus tobramycin, 10 percent, as compared with 3 percent in those who did not receive an aminoglycoside. This difference, however, was not statistically significant. It was concluded that piperacillin should be considered for antibiotic management of patients with acute cholecystitis and that further studies are necessary in patients with cholangitis to determine whether or not newer agents should replace penicillin and aminoglycoside combinations.

UR - http://www.scopus.com/inward/record.url?scp=0023625854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023625854&partnerID=8YFLogxK

M3 - Article

C2 - 3310282

AN - SCOPUS:0023625854

VL - 165

SP - 285

EP - 292

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 4

ER -